Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2023

Revenue Recognition

Schedule of disaggregation of revenues by payer types

	Three months ended				Nine months ended
	September 30,				September 30,
	2023		2022		2023		2022
(in thousands)
Insurance carriers	$	239,780	$	174,825	$	676,680	$	507,389
Laboratory and other partners		21,731		27,050		71,985		69,929
Patients		6,795		8,762		22,801		25,652
Total revenues	$	268,306	$	210,637	$	771,466	$	602,970

Schedule of total revenue by geographic area

	Three months ended				Nine months ended
	September 30,				September 30,
	2023		2022		2023		2022
(in thousands)
United States	$	259,870	$	197,066	$	746,420	$	576,169
Americas, excluding U.S.		1,288		1,155		3,652		2,426
Europe, Middle East, India, Africa		5,255		4,956		16,071		12,383
Asia Pacific and Other		1,893		7,460		5,323		11,992
Total revenues	$	268,306	$	210,637	$	771,466	$	602,970

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	September 30,		December 31,
(in thousands)	2023		2022
Assets:
Accounts receivable, net	$	255,147	$	244,385
Liabilities:
Deferred revenue, current portion	$	15,012	$	10,777
Deferred revenue, long-term portion		21,033		20,001
Total deferred revenues	$	36,045	$	30,778

Schedule of changes in the balance of deferred revenues

	September 30,			September 30,
	2023			2022
(in thousands)
Beginning balance	$	30,778	$	28,722
Increase in deferred revenues		24,553		20,268
Reclass of unbilled revenues previously deferred		—		(337)
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(9,610)		(7,877)
Revenue recognized from performance obligations satisfied within the same period		(9,676)		(12,439)
Ending balance	$	36,045	$	28,337